Can You Take Methotrexate and Prednisone Together?

Methotrexate and prednisone are not only safe to take together in most cases, they are one of the most widely used drug combinations in rheumatology. Doctors have been prescribing them as a pair for decades, and a growing body of trial data suggests the combination works better than either drug alone for several inflammatory conditions. The pairing does carry dose-dependent risks, particularly for infection, but the evidence consistently shows that low-dose prednisone added to methotrexate improves outcomes while requiring some straightforward precautions.

Why Doctors Pair These Two Drugs

Methotrexate is the backbone treatment for rheumatoid arthritis and several other autoimmune diseases. It works slowly, though, often taking weeks to months before a patient feels meaningful relief. Prednisone is a corticosteroid that tamps down inflammation fast, sometimes within hours. Combining them lets prednisone control symptoms and prevent joint damage in the early window while methotrexate builds toward its full effect. This “bridging” strategy is a cornerstone of modern RA treatment.

In a randomized trial of early RA patients, those who received methotrexate plus 10 mg of daily prednisone had less erosive joint damage after two years, better disease control, and were less likely to need the addition of stronger immunosuppressive drugs compared to those on methotrexate plus placebo.¹ Long-term follow-up of that same trial strategy found that the group initially given prednisone was less likely to eventually need expensive biologic drugs and had better X-ray results years later, without accumulating more steroid-related health problems.²

A separate trial tested whether the initial prednisone dose matters by comparing high-dose bridging, low-dose bridging, and placebo alongside methotrexate in early RA. At 12 weeks, both prednisone groups had meaningfully lower disease activity than placebo. By one year, though, all three groups had converged to similar levels of disease control, suggesting that the early burst of prednisone buys time and protects joints during the critical first months rather than changing the long-run disease trajectory on its own.³

Prednisone May Actually Soften Methotrexate Side Effects

One of the more surprising findings in recent years is that adding prednisone to methotrexate does not just help with disease control; it appears to make methotrexate itself easier to tolerate. A study analyzing data from RA patients on methotrexate-based regimens found that those who also took prednisone were roughly half as likely to report any methotrexate side effect. Nausea dropped significantly, and liver enzyme elevations, one of the more common reasons doctors reduce or stop methotrexate, were about 70 percent less likely in the prednisone group. That protective effect held regardless of the methotrexate dose and was not seen when a different add-on drug (tocilizumab) was used instead, pointing to something specific about how prednisone interacts with methotrexate’s side-effect profile.⁴

The mechanism is not fully pinned down, but laboratory work offers some clues. Both drugs appear to work together to dial down the activity of cells called osteoclasts, which are responsible for bone erosion in RA. By reducing the expression of a key receptor on immune cells that drives osteoclast formation, the combination limits the damage these cells can do, more so than either drug alone.⁵ That synergy may partly explain why joint damage outcomes improve when the two are paired.

Infection Risk Climbs With Higher Doses

Both methotrexate and prednisone suppress parts of the immune system, so combining them does increase the chance of infection. The critical variable is dose. Data from a large U.S. registry of RA patients found that prednisone at doses above 10 mg daily was linked to about a 30 percent higher rate of infections overall and a 63 percent higher rate of opportunistic infections, the kind caused by organisms that rarely threaten people with healthy immune systems.⁶ Low-dose prednisone carried a smaller and less consistent infection signal in that same analysis.

A more recent study drilled into how the two drugs interact on infection risk specifically. It found a statistically significant dose-dose interaction: bacterial infections climbed as either drug’s dose increased, but the sharpest rise occurred when both methotrexate and glucocorticoid doses were on the higher end simultaneously. The threshold the researchers flagged was glucocorticoid doses of 5 mg or more paired with methotrexate doses of 8 mg per week or more.⁷ This does not mean those doses are dangerous for everyone, but it does mean your doctor should weigh infection history, age, and other risk factors when setting your dose of each.

Gastrointestinal problems deserve separate mention. Both drugs can irritate the gut lining, and RA patients are often also taking nonsteroidal anti-inflammatory drugs (NSAIDs), creating a three-way risk for erosions and ulcers.⁸ If you are on both medications and develop persistent stomach pain, dark stools, or unexplained nausea, flag it early rather than assuming it is just a routine side effect.

What About Bone Loss From Prednisone?

One of the biggest fears patients have about long-term prednisone is osteoporosis, and reasonably so. Corticosteroids at moderate-to-high doses for extended periods are a well-known cause of bone thinning. The reassuring news from the RA literature is that when osteoporosis prevention measures are in place, adding low-dose prednisone to methotrexate does not appear to worsen bone density compared to methotrexate alone.

A study that tracked bone mineral density in early RA patients treated with or without 10 mg daily prednisone, all of whom received calcium and vitamin D supplementation, found no significant difference in bone density at the spine or hip between the two groups at any point during the trial. Both groups actually gained bone density at the lumbar spine over the first year. The factors that did predict lower bone density were older age, lower body weight, and higher disease activity, not prednisone use.⁹ The takeaway is not that prednisone is harmless to bones, but that prophylaxis works and should be standard whenever prednisone is prescribed for more than a few weeks.

Folic Acid and Other Ways to Reduce Side Effects

Folic acid supplementation is one of the simplest and most effective ways to make methotrexate safer, and it matters even more when you are combining drugs. Methotrexate works partly by interfering with folate metabolism, which is also why it causes some of its side effects, especially liver enzyme elevations and mouth sores. Taking folic acid alongside methotrexate dramatically reduces the rate at which patients have to stop the drug because of liver problems.

In a 48-week randomized trial, nearly 40 percent of RA patients on methotrexate plus placebo had to discontinue because of toxicity, primarily elevated liver enzymes. In contrast, only about 17 percent of those taking folic acid alongside methotrexate stopped for the same reason. The folate supplement did not blunt methotrexate’s effectiveness against arthritis; the improvement in disease activity was similar across all groups.¹⁰ A Cochrane systematic review covering the broader evidence base confirmed that folic or folinic acid supplementation reduces side effects without meaningfully changing how well methotrexate works.¹¹

Most rheumatologists now prescribe folic acid routinely with methotrexate. If yours has not mentioned it, ask. The usual dose is 1 mg daily or 5 mg once a week, taken on a day other than methotrexate day, though some doctors prescribe it daily without concern about timing.

Methotrexate as a Steroid-Sparing Agent

In many conditions, the goal of adding methotrexate is not just to improve disease control but to get patients off prednisone faster. This is called a “steroid-sparing” strategy, and it reflects a practical reality: while prednisone works quickly, the side effects of long-term use, including weight gain, blood sugar problems, cataracts, and skin thinning, accumulate over months and years. Methotrexate can take over the immunosuppressive role and let prednisone be tapered down or stopped.

This strategy has been tested across several diseases. In juvenile dermatomyositis, children treated with methotrexate combined with an aggressively tapered steroid course needed corticosteroids for a median of only 10 months, compared to 27 months in a control group. The cumulative prednisone dose was roughly half, and the children in the methotrexate group grew taller during the first year, likely because they spent less time on the growth-suppressing steroid.¹²

In giant cell arteritis, a condition that typically requires months of prednisone, a randomized trial found that patients who received methotrexate alongside prednisone experienced fewer relapses, with 45 percent relapsing at least once compared to 84 percent in the prednisone-plus-placebo group. The methotrexate group also used about 1,300 mg less prednisone total over the study period.¹³ A systematic analysis of the broader trial evidence concluded that methotrexate should be considered for patients at high risk for steroid side effects or those whose disease relapses repeatedly during taper.¹⁴

The pairing has also been studied in Crohn’s disease, where patients with chronically active disease despite months of prednisone were randomized to add weekly methotrexate injections or placebo. The protocol involved starting all patients on 20 mg of daily prednisone and tapering over 10 weeks, testing whether methotrexate could maintain remission as the steroid came down.¹⁵ The theme across all these conditions is consistent: methotrexate lets you use less prednisone over time, which in turn reduces the long-term toll of steroid therapy.

Vaccines and Timing Your Doses

If you are on methotrexate, vaccine timing deserves attention. Methotrexate can dampen your immune response to vaccinations, meaning you produce fewer protective antibodies after a shot. A trial studying COVID-19 booster vaccines in people with inflammatory conditions found that pausing methotrexate for two weeks around the time of vaccination significantly improved antibody responses, and the benefit persisted for at least six months. The trade-off was a temporary uptick in disease flares, though most were mild and self-managed.¹⁶

Interestingly, prednisone does not appear to cause the same problem. A study of pneumococcal vaccine responses in RA patients found that prednisolone treatment did not reduce antibody levels, while methotrexate did.¹⁷ So if you are on both drugs and getting vaccinated, the conversation with your doctor should focus on whether to pause the methotrexate, not the prednisone. Whether pausing makes sense depends on how stable your disease is and how important the vaccine is for you, a decision that varies person to person.

Pregnancy and Absolute Contraindications

There is one situation where taking methotrexate alongside prednisone, or at all, is an absolute no: pregnancy. Methotrexate causes birth defects and miscarriage and is classified as teratogenic across every major guideline.¹⁸ It should be stopped well before conception, with most guidelines recommending at least three months of washout. Prednisone, by contrast, can be used during pregnancy at low doses when the benefit outweighs the risk, making it one of the few immunosuppressants still available to pregnant patients with active autoimmune disease. If you are planning a pregnancy while on both drugs, expect your rheumatologist to discontinue the methotrexate first and potentially keep you on low-dose prednisone as a bridge until after delivery.

Beyond pregnancy, significant kidney impairment can make the combination riskier, because methotrexate is cleared by the kidneys and can accumulate to toxic levels when kidney function is reduced. Regular blood monitoring, which most rheumatologists order every one to three months anyway, catches rising drug levels and organ stress before they become dangerous. If you are skipping lab appointments, you are flying blind on the one thing most likely to make this combination go wrong.

When One Drug Gets Blamed for the Other’s Side Effects

Patients on both medications sometimes struggle to tell which drug is causing a particular symptom. Fatigue, nausea, and mood changes can come from either. A useful pattern to watch for is timing: methotrexate side effects tend to cluster in the 24 to 48 hours after the weekly dose, then fade. Prednisone side effects, especially insomnia, jitteriness, and increased appetite, tend to be more constant as long as you are taking it and worsen when the dose goes up. If you notice a new symptom, tracking whether it follows the methotrexate dosing day or seems independent of it can help your doctor figure out which medication to adjust.

Weight gain is one of the most common complaints on the combination, and it is almost entirely a prednisone effect. Methotrexate does not typically cause weight gain on its own. If weight is climbing, the conversation should be about prednisone dose reduction, not about stopping methotrexate. Similarly, hair thinning is more commonly attributable to methotrexate than to prednisone, so the drugs do have distinguishable side-effect signatures once you know what to look for.

Blood count drops, known as cytopenias, are another concern that has been studied in patients on both drugs. A meta-analysis of randomized trials involving methotrexate for rheumatic diseases noted that a substantial proportion of study participants were concurrently using corticosteroids.¹⁹ The risk of clinically significant drops in white blood cells or platelets is generally low with methotrexate at standard RA doses, but it rises when methotrexate is combined with other drugs that also suppress bone marrow function. Prednisone alone does not typically suppress blood counts, but the combination warrants regular complete blood count monitoring all the same.

Adding a Third Drug to the Mix

Many patients end up on methotrexate, prednisone, and a third immunosuppressive agent, such as a biologic or another conventional disease-modifying drug. This is standard practice in moderate-to-severe RA when two drugs are not enough. But the more immunosuppressive layers you stack, the more important dose discipline becomes. The data on infection risk cited earlier specifically noted that combinations involving higher-dose prednisone plus methotrexate plus a TNF-blocking biologic carried the steepest infection rates.⁶ Adding leflunomide to methotrexate is another escalation that has been linked to pancytopenia in case reports, meaning very low counts of all blood cell types.²⁰ None of this means triple therapy is inherently reckless, but it does mean the monitoring schedule tightens and the tolerance for missed lab work drops to zero.